Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2003

View Archived Issues

TROICA study evaluates tenecteplase for cardiac arrest

MIV-210 effective in vitro against resistant viruses

Four related series of MMP inhibitors and their use patented by Pfizer

Lilly researchers claim two novel series of tachykinin NK1 antagonists

Teijin scientists identify new piperidine-based CCR3 antagonists

Sumitomo patent covers new antidiabetic PPARalpha and/or PPARgamma agonists

New hypocholesterolemic polymers developed at Taisho

Shionogi researchers discover new NADPH oxidase inhibitors

Trial commences for ADVAX HIV/AIDS vaccine

Eculizumab granted U.S. and E.U. orphan drug designations for PNH

Preliminary phase III results for Vivitrex show reductions in heavy drinking

Allergan and Inspire sign copromotion agreement for Elestat

Encouraging outcomes for Rituxan phase II and III trials

Interim results from phase II studies of HuMax-CD4 for CTCL

GlaxoSmithKline to advance 480848 into phase III trials in 2004

INGN-225 to be studied for advanced breast cancer in phase I/II trial

Sugen identifies potential surrogate markers for SU-11248 activity

New phase II trials to evaluate KOS-862 for various cancers

Novactyl seeks licensing partner for PCL-016

Enrollment under way in second phase of BEYOND Betaferon trial

SARS vaccine induces T-cell and antibody responses in animal study

Antitumor activity of E-7070 in metastatic breast cancer

Novel strategy to block SARS virus replication

Fluoxetine safe and effective for adolescents with bulimia nervosa

Improved survival with RSR-13 plus WBRT in breast cancer patients with brain metastases

Antitumor efficacy of Bay-59-8862 in metastatic breast cancer

Novel inhibitor of Stat3 activation with activity against hematological malignancies

Improved antiemetic efficacy of aprepitant compared to standard regimen in both men and women

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...